30 Technology- EMA Approval to launch a Phase 1/2a trial in patients with Non-Cystic Fibrosis Bronchiectasis
30 Technology is thrilled to announce approval for our Phase 1/2a trial designed to evaluate the safety, tolerability, and efficacy of nebulised Nitric Oxide Formulations
30 Technology completes final patient dosing in its TB study in South Africa
30 Technology is excited to announce that we have successfully completed the final dosing for all participants enrolled in our Tuberculosis study based in South Africa.
30 Technology Holds Inaugural Scientific Advisory Board Meeting
We are delighted to announce the first meeting of 30 Technology’s newly formed Scientific Advisory Board (SAB) held in our offices in Central London.